^
    over1year
    Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models (IASLC-WCLC 2023)
    The combination of mobocertinib with amivantamab displayed synergetic efficacy in 2 independent EGFR ex20ins+ NSCLC PDX models; unique resistant molecular profiles to single-agent or combination treatments were identified. These results warrant further testing of this combination to potentially improve patient outcomes.
    Preclinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR A767dupASV • EGFR S768dupSVD
    |
    Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib)